Tiefenbacher Group
TIEFENBACHER GROUP is a purpose-driven healthcare company committed to pioneering healthcare worldwide by making pharmaceuticals more affordable, available, and better than before. Since 1963, it has been operating as a family-owned enterprise, providing solutions along the entire pharmaceutical value chain, including raw materials, finished dosage forms, and medical devices. The company emphasizes innovation, patient-centricity, and global market access, with a strong focus on quality, safety, and sustainability. It maintains a broad portfolio of high-quality APIs, finished dosage forms, and medical devices, serving over 250 European customers and operating in more than 80 countries. The company is dedicated to sustainability, having achieved EcoVadis Silver for Sustainability, and adheres to strict quality and regulatory standards. Its organizational structure is agile, vertically integrated, and values curiosity, excellence, and patient-centered innovation. The company was founded by Alfred E. Tiefenbacher in 1963 and has grown into a global leader in healthcare solutions, continuously expanding its facilities, product offerings, and market presence.
Industries
Nr. of Employees
large (251-1000)
Tiefenbacher Group
Products
API portfolio (600+ APIs across ATC groups)
Distribution and regulatory support for a broad portfolio of active pharmaceutical ingredients and excipients for human and veterinary use, manufactured at trusted GMP sites and distributed under GDP.
Finished dosage forms (180+ products, 10+ dosage forms)
Manufactured finished dosage forms across multiple routes of administration (tablets, capsules, powders, drops, inhalers, patches, eye drops), including generics, value‑added and highly potent products for global markets.
Medical devices and drug–device combinations
Engineered medical devices and drug–device combinations designed to improve delivery, adherence and patient outcomes, including devices integrated with companion digital services.
Connected dosing device with companion digital service (under development)
A connected handheld dosing device paired with a digital service platform to support individualized dosing, adherence monitoring and remote data capture (product in development and subject to regulatory clearance).
API portfolio (600+ APIs across ATC groups)
Distribution and regulatory support for a broad portfolio of active pharmaceutical ingredients and excipients for human and veterinary use, manufactured at trusted GMP sites and distributed under GDP.
Finished dosage forms (180+ products, 10+ dosage forms)
Manufactured finished dosage forms across multiple routes of administration (tablets, capsules, powders, drops, inhalers, patches, eye drops), including generics, value‑added and highly potent products for global markets.
Medical devices and drug–device combinations
Engineered medical devices and drug–device combinations designed to improve delivery, adherence and patient outcomes, including devices integrated with companion digital services.
Connected dosing device with companion digital service (under development)
A connected handheld dosing device paired with a digital service platform to support individualized dosing, adherence monitoring and remote data capture (product in development and subject to regulatory clearance).
Services
Global procurement, supplier qualification and distribution of APIs and raw materials with regulatory support (EU DMF), multi‑sourcing strategies and GDP‑compliant logistics.
On‑site formulation and analytical development for generics, value‑added and innovative products across multiple dosage forms, including highly potent formulations and support for dossier generation.
Manufacturing of finished dosage forms from clinical batches to commercial volumes with primary/secondary packaging and multi‑site production in GMP‑inspected facilities.
Analytical testing, method validation/transfer, dissolution testing and ICH stability studies to support development, release and regulatory submissions.
Strategic regulatory consulting, preparation and submission of marketing authorization dossiers, lifecycle maintenance and local regulatory adaptation for global markets.
Project‑based design, engineering, verification/validation and regulatory alignment for medical devices and combination products, including digital companion service integration.
Global procurement, supplier qualification and distribution of APIs and raw materials with regulatory support (EU DMF), multi‑sourcing strategies and GDP‑compliant logistics.
On‑site formulation and analytical development for generics, value‑added and innovative products across multiple dosage forms, including highly potent formulations and support for dossier generation.
Manufacturing of finished dosage forms from clinical batches to commercial volumes with primary/secondary packaging and multi‑site production in GMP‑inspected facilities.
Analytical testing, method validation/transfer, dissolution testing and ICH stability studies to support development, release and regulatory submissions.
Strategic regulatory consulting, preparation and submission of marketing authorization dossiers, lifecycle maintenance and local regulatory adaptation for global markets.
Project‑based design, engineering, verification/validation and regulatory alignment for medical devices and combination products, including digital companion service integration.
Expertise Areas
- API distribution and portfolio management
- GMP warehouse operations and GDP distribution
- Supplier qualification and GMP auditing
- Finished dosage form formulation and development
Key Technologies
- Oral solid dosage formulation
- Transdermal patch manufacturing
- Inhaler device engineering
- High‑potency containment technology
News & Updates
New product and analytical development labs and offices at AET Laboratories India.
Development of high potent drugs in Hyderabad, India.
Expansion of the Cyprus site for manufacturing and development.
Initiation of development for a digital health and drug combination solution.
Approval of a new chemical entity for sleep disorders.
New product and analytical development labs and offices at AET Laboratories India.
Development of high potent drugs in Hyderabad, India.
Expansion of the Cyprus site for manufacturing and development.
Initiation of development for a digital health and drug combination solution.
Approval of a new chemical entity for sleep disorders.